CathWorks' Groundbreaking Achievement in Clinical Trials
CathWorks, a leader in medical device innovations, has achieved an important milestone with the completion of enrollment for its pivotal Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment study, referred to as the ALL-RISE trial. This step is crucial as it marks a significant advancement in interventional cardiology, focusing on both clinical and economic benefits.
Insights into the ALL-RISE Study
The ALL-RISE study involved over 1,924 patients from 59 different sites spanning various continents, including Asia, Europe, and the Middle East. As part of this clinical trial, participants presenting with intermediate coronary stenoses requiring thorough physiological assessment were randomly assigned to receive either FFRangio-guided treatment or traditional invasive pressure wire-guided methods.
A New Standard in Cardiovascular Assessments
This trial is notably the first randomized controlled trial in the U.S. that evaluates clinical results through an angiography-based tool specifically designed for assessing physiological lesions. The innovative approach promises to redefine treatment pathways for coronary artery disease (CAD).
Acknowledgments from Leading Researchers
Dr. Ajay J. Kirtane, along with Principal Investigators Dr. William Fearon and Dr. Allen Jeremias, expressed their gratitude towards everyone involved in this remarkable project. They underlined the impressive speed of enrollment, which mirrors the increasing global acceptance of the FFRangio technology. The team eagerly anticipates sharing insightful results upon completion of patient follow-ups.
CathWorks Leadership Comments on Study Impact
Reflecting on this achievement, Alex Froimovich, M.D., CathWorks' Senior Director of Clinical Affairs, highlighted that completing the ALL-RISE enrollment signifies a pivotal moment for their mission to enhance cardiovascular disease management. He emphasized that the insights gathered from this trial will contribute to establishing FFRangio as a fundamental technology for cardiac assessments.
Understanding the Context of Cardiovascular Disease
Cardiovascular disease continues to be a leading health threat globally, with significant mortality rates reported annually. Research indicates that coronary artery disease accounts for more than 40% of cardiovascular-related deaths. CathWorks aims to highlight how the findings from the ALL-RISE study may lead to enhanced patient outcomes and efficiencies within healthcare systems.
Company Overview: CathWorks
CathWorks specializes in advancing digital health technology that aims to enhance patient care. The company's FFRangio System integrates artificial intelligence and advanced computational methods, fundamentally changing how cardiovascular health is assessed. This device simplifies the process by extracting physiological insights from standard angiograms without the need for invasive procedures.
Frequently Asked Questions
1. What is the primary focus of the ALL-RISE trial?
The ALL-RISE trial focuses on evaluating the clinical and economic benefits of the FFRangio System in the context of diagnosing and treating coronary artery disease.
2. How many patients participated in the trial?
Over 1,924 patients were enrolled in the ALL-RISE trial across 59 sites globally.
3. What distinguishes the ALL-RISE study from other trials?
This study is unique as it is the first randomized controlled trial in the U.S. to utilize an angiography-based tool for physiological assessment of coronary lesions.
4. Who are the leading researchers involved in the study?
The trial is led by Dr. Ajay J. Kirtane, with significant contributions from Dr. William Fearon and Dr. Allen Jeremias.
5. What is the long-term vision for the FFRangio System?
CathWorks envisions the FFRangio System becoming a new standard of care, enhancing diagnosis and treatment through reliable physiological data extracted from angiograms.
